Sequana Medical lists on Euronext Brussels

Capital raised through IPO will enable the execution of Sequana Medical’s strategy

Brussels, 11 February 2019 – Belgian-based medtech company Sequana Medical NV (ticker symbol: SEQUA) today began trading on Euronext Brussels (Compartment C) with an initial market capitalisation of approximately €107.2 million. This transaction demonstrates the attractiveness of Euronext as the leading stock exchange for European biotech and medtech companies. With this operation, Sequana Medical joins a large franchise of 89 life science companies (52 biotech and 37 medtech companies) currently listed on Euronext’s markets, representing a total market capitalisation of €22 billion per 31 January 2019.

Sequana Medical NV is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical's first product is the alfapump®, a fully implantable, programmable, wirelessly-charged, battery-powered system. It has been approved in Europe for the treatment of liver refractory ascites and malignant ascites and has shown a strong performance in multiple clinical studies and over 650 implants. The alfapump® has recently been granted breakthrough device designation by the US FDA. The Company is also developing alfapump® DSR (Direct Sodium Removal), a novel and proprietary approach to the treatment of volume overload in heart failure for which a first-in-human study is ongoing.

Founded in Switzerland in 2006, Sequana has established its new corporate headquarters in Ghent, Belgium, in order to benefit from Belgium’s attractive healthcare ecosystem and ultimately to list on Euronext Brussels, one of the most dynamic stock exchanges in Europe for life sciences IPOs.

With an initial reference price set at €8.5 per share, Sequana Medical’s initial market capitalization stands at €107.2 million.

Ian Crosbie, Chief Executive Officer of Sequana Medical, said: "We are very pleased with the successful closing of our IPO on Euronext Brussels, which is renowned for being very supportive of high-quality listings in the healthcare space. The funds raised will support our commercial and clinical development with the goal to make the alfapump® and alfapump® DSR available to a broader patient group and address important unmet medical needs. We would like to thank all of our existing shareholders and our new investors for their support in making this transaction a success and we are looking forward to entering this exciting new phase for our Company."

To mark Sequana Medical’s first trading day, Ian Crosbie, Chief Executive Officer of Sequana Medical, rang the bell to open the markets in Brussels today.

About Sequana Medical
Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.

Sequana Medical's alfapump® is a fully implantable, programmable, wirelessly-charged, battery-powered system that is CE-marked for the management of i) refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and ii) malignant ascites (with a life expectancy of six months or less). The number of patients with liver refractory ascites is forecast to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis).

Over 650 alfapump® systems have been implanted and since April 2018, the alfapump® has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines for decompensated cirrhosis. In January 2019, the FDA has granted Breakthrough Device designation for the alfapump® for the treatment of liver recurrent or refractory ascites. The alfapump® MOSAIC North American IDE feasibility study in patients with liver refractory or recurrent ascites has been completed and results were presented at the AASLD (American Association for the Study of Liver Diseases) annual meetings in October 2017 and November 2018. The alfapump® has not yet received regulatory approval in the U.S.

The alfapump® is one of the first safe and effective, long-term alternatives to large-volume paracentesis which is a lengthy, invasive and painful procedure, only providing short-term symptomatic relief, requiring hospital visits and placing a significant burden on the healthcare system and patient quality of life. By automatically and continuously moving ascites to the bladder, where the body eliminates it naturally through urination, the alfapump® prevents fluid build-up and its possible complications, improving patient quality of life and nutrition, and potentially reducing hospital visits and healthcare costs. The alfapump® DirectLink technology allows clinicians to receive pump performance information and more effectively manage patients treated by the alfapump®.

Sequana Medical is developing the alfapump® DSR, built upon the proven alfapump® platform, to deliver a convenient and fully implanted system for Direct Sodium Removal ("DSR") therapy, a novel and proprietary approach for the management of volume overload in heart failure. Data from animal studies presented at EuroPCR 2018 and HFSA 2018 indicate that DSR therapy is effective and safe. A first in human study for DSR therapy is ongoing. Treatment of volume overload in diuretic-resistant heart failure patients is a major clinical challenge. There are an estimated one million hospitalisations due to heart failure in the U.S. each year, of which 90% are due to symptoms of volume overload. The estimated cost of heart failure-related hospitalisations in the U.S. is $13 billion a year.

Sequana Medical is headquartered in Ghent, Belgium and investors include NeoMed Management, LSP (Life Science Partners), VI Partners, BioMedPartners, Capricorn Venture Partners, Entrepreneur's Fund, Salus Partners, Newton Biocapital, PMV and SFPI-FPIM. For further information, please visit www.sequanamedical.com.

Attachments Available Languages
Download press releaseen

Sobre a Euronext
A Euronext é a bolsa líder na Zona Euro, cobrindo a Bélgica, França, Holanda, Irlanda, Portugal e Reino Unido. Com 1300 emitentes e uma capitalização bolsista de cerca de 3.4 biliões de euros no final de Dezembro de 2018, a Euronext apresenta uma representação inigualável de mais de 24 emitentes de Morningstar® Eurozone 50 Index℠, bem como uma base sólida e diversificada de clientes nacionais e internacionais. A Euronext opera mercados a contado e de derivados, regulamentados e transparentes e é o maior centro mundial de dívida e fundos cotados. A sua oferta de produtos inclui Ações, ETFs, Warrants e Certificados, Obrigações, Derivados, Mercadorias e Índices. A Euronext utiliza, também, a sua experiência na gestão de mercados, fornecendo tecnologia e serviços de gestão a terceiras entidades. Para além do seu principal mercado regulamentado, a Euronext opera ainda o Euronext GrowthTM e o Euronext AccessTM , simplificando a admissão ao mercado de capitais para as PMEs.
Siga-nos e aceda à informação mais recente através do Twitter (twitter.com/euronext) e do LinkedIn (linkedin.com/company/euronext).

Disclaimer
O conteúdo desta press release é unicamente informativo e não constitui uma recomendação para efectuar investimentos. O conteúdo desta publicação é prestado “como se apresenta”, sem representação ou garantia de qualquer natureza. Apesar de todo o cuidado para assegurar a exactidão do conteúdo, a Euronext não garante a sua fiabilidade ou a sua completude. A Euronext não se considera responsável por qualquer perda ou dano de qualquer natureza, resultante do uso, actuação ou confiança depositada na informação facultada. Nenhuma informação contida ou mencionada nesta publicação constitui base para a celebração de qualquer contrato. A criação de direitos e de obrigações referentes a instrumentos financeiros que são negociados nos mercados operados pelas subsidiárias da Euronext só podem resultar das regras aplicáveis ao operador de mercado em questão. A Euronext é titular de todos os direitos contidos ou relacionados com esta publicação. 

 

Este press release reporta-se, apenas, à presente data. A Euronext refere-se à Euronext N.V. e suas subsidiárias. A informação relativa às marcas e aos direitos de propriedade intelectual da Euronext consta em www.euronext.com/terms-use.

© 2019, Euronext N.V. – Todos os direitos reservados.